The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 195-page report you will receive 131 tables and 66 figures– all unavailable elsewhere.
The 195-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Cancer Type: • Lung Cancer • Breast Cancer: HER-2 Positive, HR Positive, TNBC • Colorectal Cancer • Other Cancers
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Biopsy Type: • Tissue Biopsy • Liquid Biopsy
• Global Precision Cancer Diagnostics Tests Market revenues forecast from 2019-2029 by Regional and National market: • US • Japan • Germany • France • Italy • UK • Spain • China • India • Brazil • Russia
The forecast of each country is further broken down by cancer type and biopsy type.
• Profile of the selected leading companies: • Abbott Laboratories • Agilent Technologies, Inc. • bioMerieux SA • Genomic Health, Inc. • Illumina, Inc. • Myriad Genetics, Inc. • Qiagen N.V. • Roche Holding AG • Siemens Healthineers • Thermo Fisher Scientific, Inc.
• Analysis of factors that drive and restrain the global precision cancer diagnostics tests market
• Key Questions Answered by this Report: • How the global precision cancer diagnostic tests market is evolving? • What are the drivers, restraints and opportunities in the global precision cancer diagnostic tests market? • How will each of the sub-markets of the precision cancer diagnostic tests market develop over the period of study? • Who are the leading players in the precision cancer diagnostic tests market and what are their future perspective during the period of study? • What are the recent developments in the global precision cancer diagnostic tests market?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Precision Cancer Diagnostics Test Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Global Precision Cancer Diagnostic Tests Market Overview 1.2 Why You Should Read This Report 1.3 How the Report Delivers 1.4 Key Questions Answered by This Analytical Report Include 1.5 Who is This Report For? 1.6 Methodology 1.6.1 Primary Research 1.6.2 Secondary Research 1.6.3 Market Evaluation & Forecasting Methodology 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 2. Introduction to Precision Medicine 2.1 Evolution and Brief History of Precision Medicine 2.2 Key Benefits of Precision Medicine 2.3 Precision Medicine: Key Application Areas 2.4 Precision Medicine: Key Elements 2.5 Precision Medicine: Different Type of Data Used by Big Data Companies 2.6 Precision Medicine: Area of Interest
3. Qualitative Analysis 3.1 Market Dynamics 3.1.1 Drivers and Opportunities 3.1.1.1 Growing Volume of Precision Cancer Diagnostic Tests Receiving Regulatory Approval 3.1.1.2 Improving Reimbursement Scenario in the Developed Markets 3.1.1.3 Government Support for Precision Medicine 3.1.1.4 Precision Cancer Assays Based on Liquid Biopsies Offer High Growth Opportunities 3.1.1.5 Growing Aging Population and Cancer Prevalence 3.1.2 Restraints and Challenges 3.1.2.1 High Cost of Precision Tests and Therapies 3.1.2.2 Limited Access and Delay in Test Results 3.2 Regulatory Analysis: Precision Diagnostics (Companion Diagnostics) 4. Precision Cancer Diagnostic Tests Market by Cancer Type 4.1 Lung Cancer 4.2 Breast Cancer 4.2.1 HER2 Positive Breast Cancer 4.2.2 Hormone Receptor (HR)-positive Breast Cancer 4.2.3 Triple Negative Breast Cancer 4.3 Colorectal Cancer 4.4 Blood Cancer 4.5 Stomach (Gastric) Cancer 4.6 Other Cancers
5. Precision Cancer Diagnostic Tests Market by Biopsy Method 5.1 Tissue Biopsy 5.2 Liquid Biopsy
6. Leading National Precision Cancer Diagnostic Tests Markets, 2018-2029 6.1 US 6.2 Japan 6.3 Germany 6.4 France 6.6 Italy 6.6 UK 6.7 Spain 6.8 China 6.9 India 6.10 Brazil 6.11 Russia
7. Leading Companies in the Precision Cancer Diagnostic Tests Market 7.1 Roche Holding AG 7.1.1 Roche: Precision Cancer Diagnostics Product Portfolio 7.1.2 Sales and Recent Performance Analysis, 2017 7.1.3 Recent Developments 7.1.3.1 FDA Approval for triple-Negative Breast Cancer Test 7.1.3.2 Collaboration with Phoenix Molecular Designs (PhoenixMD) 7.1.3.3 Partnership with Merck to develop pan-cancer companion diagnostic test 7.1.3.4 Collaboration Agreement with Daiichi Sankyo 7.1.3.5 FDA Approval for cobas EGFR Mutation Test v2 as a companion diagnostic test (CDx) with IRESSA 7.1.3.6 Roche acquires Foundation Medicine 7.1.3.7 Collaboration with Five Prime Therapeutics 7.1.3.8 Extension of Collaboration Agreement with Pierre Fabre 7.1.3.9 FDA Approval for cobas EGFR Mutation Test v2 as a Companion Diagnostic with Tagrisso 7.1.3.10 FDA Approval for Ventana ALK (D5F3) companion diagnostic for Alecensa 7.1.3.11 CE Mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody 7.1.3.12 FDA Approval for VENTANA ALK (D5F3) CDx Assay 7.1.3.13 FDA Approval for cobas EGFR Mutation Test v2 7.2 Illumina, Inc. 7.2.1 Sales and Recent Performance Analysis, 2017 7.2.2 Illumina: Precision Cancer Diagnostics Product Portfolio 7.2.3 Recent Developments 7.2.3.1 Partnership with Loxo Oncology 7.2.3.2 FDA Approval for Praxis Extended RAS Panel 7.3 Thermo Fisher Scientific, Inc. 7.3.1 Sales and Recent Performance Analysis, 2017 7.3.2 Thermo Fisher: Precision Cancer Diagnostics Product Portfolio 7.3.3 Recent Developments 7.3.3.1 Agreement with Daiichi Sankyo and Takeda Pharmaceutical 7.3.3.2 Companion Diagnostic Partnership with Spectrum Pharmaceuticals, Inc. 7.3.3.3 Companion Diagnostic Development Agreement with Blueprint Medicines 7.3.3.4 Companion Diagnostic Partnership with Agios Pharmaceuticals, Inc. 7.4 Qiagen, N.V. 7.4.1 Sales and Recent Performance Analysis, 2018 7.4.2 Qiagen: Precision Cancer Diagnostics Product Portfolio 7.4.3 Recent Developments 7.4.3.1 Collaboration with Novartis 7.4.3.2 Launch of the QIAscreen HPV PCR Test 7.4.3.3 Launch of Innovative Sample to Insight workflows 7.4.3.4 FDA Approval to Expand Use of EGFR Test 7.4.3.5 Collaboration with Japan’s clinical laboratory testing company, SRL, Inc. 7.4.3.6 Public-private Alliance in the U.K. 7.4.3.7 Launch of AdnaTest Liquid Biopsy Kits in Prostate and Lung Cancer 7.4.3.8 Partnership with Natera 7.4.3.9 Launch of Predictive therascreen PITX2 Test in Europe 7.4.3.10 FDA Clearance for JAK2 Test 7.4.3.11 FDA Approval to Expand Use of EGFR test in Lung Cancer 7.4.3.12 Partnership with Clinical Genomics 7.4.3.13 Partnership with Bristol-Myers Squibb 7.4.3.14 Commercialisation of the Research Use Only AdnaTest Prostate Cancer Panel AR-V7 7.4.3.15 FDA Clearance of JAK2 Test for Leukemia 7.5 Abbott Laboratories 7.5.1 Abbott: Precision Cancer Diagnostics Product Portfolio 7.5.2 Sales and Recent Performance Analysis, 2017 7.5.3 Recent Developments 7.5.3.1 FDA Approvals 7.6 bioMérieux SA 7.6.1 bioMérieux: Precision Cancer Diagnostics Product Portfolio 7.6.3 Recent Developments 7.7 Agilent Technologies, Inc. 7.7.1 Agilent Technologies: Precision Cancer Diagnostics Product Portfolio 7.7.2 Sales and Recent Performance Analysis, 2018 7.7.3 Recent Developments 7.7.3.1 Expanded FDA Approval for Urothelial Carcinoma 7.7.3.2 Expanded FDA Approval for Cervical Cancer 7.7.3.3 Acquisition of Lasergen, Inc. 7.7.3.4 Expanded FDA Approval for Gastric or Gastroesophageal Junction (GEJ) Cancer 7.7.3.5 Expanded FDA Approval for PD-L1 IHC 28-8 pharmDx 7.7.3.6 Introduction of the AriaDx Real-Time PCR System 7.7.3.7 Agreement with Agendia, Inc. 7.8 Siemens Healthineers (A Division of Siemens AG) 7.8.1 Siemens: Precision Cancer Diagnostics Product Portfolio 7.8.2 Sales and Recent Performance Analysis, 2018 7.8.3 Recent Developments 7.9 Myriad Genetics, Inc. 7.9.1 Myriad Genetics: Precision Cancer Diagnostics Product Portfolio 7.9.2 Sales and Recent Performance Analysis, 2017 7.9.3 Recent Developments 7.9.3.1 Expansion of Companion Diagnostic Partnership 7.9.3.2 Approval of BRACAnalysis CDx for Advanced Ovarian Cancer Therapy- Lynparza 7.9.3.3 Approval of BRACAnalysis CDx for advanced ovarian cancer therapy- TALZENNA 7.9.3.4 Laboratory Agreement with Pfizer 7.9.3.5 Approval of BRACAnalysis CDx for Metastatic Breast Cancer Therapy- Lynparza 7.9.3.6 Expanded Research Collaboration with AstraZeneca 7.9.3.7 Companion Diagnostic Collaboration with Clovis Oncology 7.9.3.8 Companion Diagnostic Collaboration with BeiGene 7.10 Genomic Health, Inc. 7.10.1 Genomic Health: Precision Cancer Diagnostics Product Portfolio 7.10.2 Sales and Recent Performance Analysis, 2017 7.10.3 Recent Developments 7.10.3.1 Expansion of Collaboration with Biocartis 7.10.3.2 Launch of Oncotype DX AR-V7 Nucleus Detect 7.10.3.3 Research Collaboration with Janssen Pharmaceuticals 7.10.3.4 Strategic Collaboration with Cleveland Diagnostics 7.10.3.5 Agreement with Biocartis to Develop an Idylla IVD Oncotype DX Breast Cancer Test
8. Conclusions 8.1 The Precision Cancer Diagnostic Tests Market Will Exhibit Lucrative Growth through 2029 8.2 Lung Cancer is the Largest Submarket 8.3 Liquid Biopsy Based Diagnostic Tests Will Offer Significant Growth Opportunities 8.4 Prominent Companies in the Market 8.5 Leading Regional Markets 8.6 Concluding Remarks Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain
List of Tables Table 2.1 Key Benefits of Precision Medicine Table 2.2 Key Elements of Precision Medicine Table 4.1 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.2 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.3 Global Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029 Table 4.4 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.5 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.6 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.7 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.8 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.9 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.10 Global Precision Cancer Diagnostic Tests Market for Breast Cancer by Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029 Table 4.11 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.12 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.13 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.14 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.15 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.16 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.17 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.18 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.19 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.20 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.21 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.22 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.23 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.24 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.25 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.26 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 4.27 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 4.28 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 5.1 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 5.2 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 5.3 Global Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue ($m), Market Share (%), 2018 vs. 2024 vs. 2029 Table 5.4 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 5.5 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 5.6 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2018-2024 Table 5.7 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), Annual Growth (%) and CAGR (%), 2024-2029 Table 6.1 Precision Cancer Diagnostic Tests Market: Regional Sales ($m) and Market Shares (%), 2018, 2024 and 2029 Table 6.2 Precision Cancer Diagnostic Tests Market: National and Regional Revenue Forecasts ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.3 Precision Cancer Diagnostic Tests Market: National and Regional Revenue Forecasts ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.4 US Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.5 US Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.6 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.7 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.8 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.9 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.10 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.11 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.12 Japanese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.13 Japanese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.14 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.15 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.16 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.17 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.18 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.19 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.20 German Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.21 German Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.22 German Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.23 German Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.24 German Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.25 German Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.26 German Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.27 German Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.28 French Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.29 French Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.30 French Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.31 French Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.32 French Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.33 French Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.34 French Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.35 French Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.36 Italian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.37 Italian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.38 Italian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.39 Italian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.40 Italian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.41 Italian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.42 Italian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.43 Italian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.44 UK Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.45 UK Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.46 UK Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.47 UK Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.48 UK Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.49 UK Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.50 UK Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.51 UK Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.52 Spanish Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.53 Spanish Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.54 Spanish Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.55 Spanish Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.56 Spanish Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.57 Spanish Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.58 Spanish Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.59 Spanish Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.60 Chinese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.61 Chinese Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.62 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.63 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.64 Chinese Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.65 Chinese Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.66 Chinese Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.67 Chinese Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.68 Indian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.69 Indian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.70 Indian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.71 Indian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.72 Indian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.73 Indian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.74 Indian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.75 Indian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.76 Brazilian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.77 Brazilian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.78 Brazilian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.79 Brazilian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.80 Brazilian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.81 Brazilian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.82 Brazilian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.83 Brazilian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.84 Russian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.85 Russian Precision Cancer Diagnostic Tests Market: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.86 Russian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.87 Russian Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.88 Russian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.89 Russian Precision Breast Cancer Diagnostic Tests Market, By Subtype: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 6.90 Russian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2018-2024 Table 6.91 Russian Precision Cancer Diagnostic Tests Market, by Biopsy Type: Revenue Forecast ($m), Annual Growth (%), and CAGR (%), 2024-2029 Table 8.1 Precision Cancer Diagnostic Tests Market: Submarket (Cancer Type) Forecasts ($m) and Market Shares (%), 2018, 2024 and 2029 Table 8.2 Precision Cancer Diagnostic Tests Market: Submarket (Biopsy type) Forecasts ($m) and Market Shares (%), 2018, 2024 and 2029 Table 8.3 Precision Cancer Diagnostic Tests National Market: Revenue Forecasts ($m) and Market Shares (%), 2018, 2024, and 2029
List of Figures Figure 1.1 Global Precision Cancer Diagnostic Tests Market – Segmentation by Cancer Type Figure 1.2 Global Precision Cancer Diagnostic Tests Market – Segmentation by Biopsy Method Figure 1.3 Global Precision Cancer Diagnostic Tests Market – Segmentation by Geography Figure 2.1 History of Precision Medicine Figure 2.2 Key Areas of Application of Precision Medicine Figure 2.3 Key Different Type of Data Used by Big Data Companies in Precision Medicine Figure 2.4 Key Areas of Interest of Precision Medicine Figure 4.1 Global Precision Cancer Diagnostic Tests Market for Lung Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.2 Global Precision Cancer Diagnostic Tests Market for Breast Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.3 Global Precision Cancer Diagnostic Tests Market for HER2 Positive Breast Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.4 Global Precision Cancer Diagnostic Tests Market for HR Positive Breast Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.5 Global Precision Cancer Diagnostic Tests Market for TNBC: Market Forecast Revenue ($m), 2018-2029 Figure 4.6 Global Precision Cancer Diagnostic Tests Market for Colorectal Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.7 US Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.8 German Precision Cancer Diagnostic Tests Market for Blood Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.9 US Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.10 German Precision Cancer Diagnostic Tests Market for Gastric Cancer: Market Forecast Revenue ($m), 2018-2029 Figure 4.11 Global Precision Cancer Diagnostic Tests Market for Other Cancers: Market Forecast Revenue ($m), 2018-2029 Figure 5.1 Global Precision Cancer Diagnostic Tests Market for Tissue Biopsy: Market Forecast Revenue ($m), 2018-2029 Figure 5.2 Global Precision Cancer Diagnostic Tests Market for Liquid Biopsy: Market Forecast Revenue ($m), 2018-2029 Figure 6.1 Global Precision Cancer Diagnostic Tests National Market Share (%), 2018 Figure 6.2 Global Precision Cancer Diagnostic Tests National Market Share (%), 2029 Figure 6.3 US Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.4 US Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.5 US Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.6 US Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.7 Japanese Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.8 Japanese Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.9 Japanese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.10 Japanese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.11 German Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.12 German Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.13 German Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.14 German Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.15 French Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.16 French Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.17 French Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.18 French Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.19 Italian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.20 Italian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.21 Italian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.22 Italian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.23 UK Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.24 UK Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.25 UK Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.26 UK Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.27 Spanish Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.28 Spanish Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.29 Spanish Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.30 Spanish Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.31 Chinese Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.32 Chinese Precision Cancer Diagnostic Tests Market, by Cancer Type: Revenue, 2018-2029 Figure 6.33 Chinese Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.34 Chinese Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.35 Indian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.36 Indian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.37 Indian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.38 Indian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.39 Brazilian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.40 Brazilian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.41 Brazilian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.42 Brazilian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029 Figure 6.43 Russian Precision Cancer Diagnostic Tests Revenue ($m), 2018-2029 Figure 6.44 Russian Precision Cancer Diagnostic Tests Market by Cancer Type: Revenue, 2018-2029 Figure 6.45 Russian Precision Breast Cancer Diagnostic Tests Market by Subtype: Revenue, 2018-2029 Figure 6.46 Russian Precision Cancer Diagnostic Tests Market by Biopsy Type: Revenue, 2018-2029
Abbott Laboratories Agendia, Inc. Agilent Technologies, Inc. Agios Pharmaceuticals, Inc. Alere Amgen Amoy Diagnostics Assurex AstraZeneca BeiGene Biocartis N.V. bioMérieux SA Blueprint Medicines Corporation Boehringer Ingelheim Bristol-Myers Squibb Celgene Cleveland Diagnostics, Inc. Clinical Genomics Clovis Oncology Daiichi Sankyo DAKO DarwinHealth Epic Sciences, Inc. Five Prime Therapeutics, Inc. Foundation Medicine Genentech Genomic Health, Inc. GRAIL, Inc. HealthWell Foundation HeiScreen Helix Holdings Illumina, Inc. Invivoscribe Janssen Pharmaceuticals Konica Minolta Precision Medicine Japan, Inc. Lasergen, Inc. Loxo Oncology Medgenome Merck Laboratories Metafora Biosystems Myriad Genetic Laboratories Myriad Genetics, Inc. NanoString Technologies Natera Novartis Novogene Co. Pfizer PhoenixMD Pierre Fabre Qiagen, N.V. Riken Genesis Roche Holding AG Siemens Healthineers Spectrum Pharmaceuticals, Inc. SRL, Inc. St. Jude Medical Strand Lifesciences Takeda Pharmaceutical Tarceva Thermo Fisher Scientific, Inc. Tianjin Novogene Bioinformatics Technology Company LTD Xcode Lifesciences
List of Organizations Mentioned in the Report American Lung Association American Medical Association American Society for Clinical Pathology American Society of Clinical Oncology Association for Molecular Pathology Bpifrance Centers for Medicare & Medicaid Services Chinese National Medical Products Administration College of American Pathologists Columbia University Irving Medical Center Columbia University Vagelos College of Physicians and Surgeons European Medicines Agency Health Innovation Manchester Heidelberg University Women’s Hospital Japanese Pharmaceuticals and Medical Device Agency Ministry of Health, Labor and Welfare National Cancer Institute National Coordinator for Health Information Technology National Institutes of Health Pharmaceutical and Medical Devices Agency
Download sample pages
Complete the form below to download your free sample pages for Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029
The latest research report from business intelligence provider Visiongain offers comprehensive analysis of the Grid Scale Battery Storage market. Visiongain...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
Immuno-Oncology Clinical Trials market is valued at US$6,849.8 million in 2023 and is projected to grow at a CAGR of 11.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
